COVID19 - USCOM1A sales, page-38

There has been some success in MERS vaccines in animals - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356267/

Recognising funding and a lack of access to animal models slowed SARS and MERS vaccines considerably. - https://link.springer.com/article/10.1007%2Fs40121-020-00300-x

But I don't think a vaccine is of particular relevance to revenue given one won't be around en-mass for at least 12 months and hopefully USCOM's products are seen as part of preparations for future pandemics and managing long term impacts like fibrosis. Developments in treatment is of much greater relevance and will more likely push us in or out of the market regarding Covid.